Provided by Tiger Trade Technology Pte. Ltd.

Addex Therapeutics Ltd

3.65
-0.2700-6.89%
Post-market: 3.650.00000.00%19:12 EDT
Volume:22.80K
Turnover:85.62K
Market Cap:6.40M
PE:-0.39
High:3.87
Open:3.86
Low:3.63
Close:3.92
52wk High:12.05
52wk Low:3.63
Shares:1.75M
Float Shares:1.08M
Volume Ratio:0.46
T/O Rate:2.11%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-9.2717
EPS(LYR):-9.4830
ROE:-122.28%
ROA:-23.59%
PB:1.58
PE(LYR):-0.38

Loading ...

Press Release: ADDEX Raises USD 2.8 Million Through Its ATM Agreement and Extends Cash Runway to the Fourth Quarter 2027

Dow Jones
·
Aug 26

NASDAQ Trade Halt Volatility Trading Pause at 02:50 Pm

Reuters
·
Aug 21

Addex Therapeutics announces publication of new ADX71743 preclinical research

TIPRANKS
·
Jul 08

Press Release: Addex Announces Publication of Research Highlighting Therapeutic Potential of Mglu7 Modulation in Regulating Sleep and Wakefulness

Dow Jones
·
Jul 08

Press Release: Addex Shareholders Approve All Resolutions at Annual General Meeting

Dow Jones
·
Jun 30

Addex Therapeutics Reports Q1 2026 Net Loss Of CHF 1.71M Versus CHF 1.47M A Year Ago, Cash CHF 0.9M

Benzinga Earnings
·
Jun 25

Press Release: Addex Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Dow Jones
·
Jun 25

Press Release: Addex Therapeutics to Report 2026 First Quarter Financial Results and Host Conference Call on June 25, 2026

Dow Jones
·
Jun 22

Press Release: Addex Convenes Annual General Meeting 2026

Dow Jones
·
Jun 05

Addex Closes 2025 With CHF 6.7M Net Loss And CHF 1.6M Cash, Regains ADX71149 Rights And Invests In Stalicla

Benzinga Earnings
·
Apr 30

Press Release: Addex Reports Full Year 2025 Financial Results and Provides Corporate Update

Dow Jones
·
Apr 30

Addex Therapeutics announces GABAB PAM candidate data

TIPRANKS
·
Apr 29

Press Release: Addex GABAB PAM Candidate Demonstrates Solid Anti-Tussive Activity in Bleomycin IPF-Related Chronic Cough Model

Dow Jones
·
Apr 29

Addex Therapeutics says spin-out company to complete NTX-253 study in Q2

TIPRANKS
·
Apr 23

Press Release: Addex Spin-Out Company Neurosterix on Track to Complete Phase 1 Clinical Study of NTX-253 for Schizophrenia in Q2 2026

Dow Jones
·
Apr 23

Press Release: Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Non-Human Primate Chronic Cough Model

Dow Jones
·
Apr 21

Addex Therapeutics Ltd – ADR trading resumes

TIPRANKS
·
Mar 19

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:56 AM

Reuters
·
Mar 18

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:58 AM

Reuters
·
Mar 11